CalAmp
CAMPCAMP4 Therapeutics is a clinical-stage biopharmaceutical company focused on developing a new class of RNA-targeting therapeutics designed to upregulate gene expression.
Earnings
Next report
Aug 13, 2026 (in a month)Revenue estimate$1.6M
EPS estimate-$0.24
Valuation & ratios
Segments
By segment
Competitors
By market cap
By revenue growth
Profile
CAMP4 Therapeutics is a clinical-stage biopharmaceutical company focused on developing a new class of RNA-targeting therapeutics designed to upregulate gene expression. By targeting regulatory RNAs (regRNAs), the company aims to restore healthy protein levels to treat a broad range of genetic diseases, particularly those caused by haploinsufficiency.
Competitive position
A pioneer in the regRNA space with a proprietary platform capable of systematically identifying druggable enhancer and promoter sequences for gene upregulation.
GeographiesUnited States, Europe
Customer segmentsRare disease patients, Healthcare providers, Strategic partners
Business modelR&D intensive, Licensing and Royalties, Drug Development
SuppliersContract research organizations (CROs), Raw material suppliers for ASO synthesis, Academic research institutions
CustomersSpecialty pharmacies, Hospitals and clinics, Strategic pharmaceutical partners
Questions, answered.
- What is CalAmp's market cap?
- CalAmp (CAMP) has a market capitalization of $230.0M and trades on XNAS.
- What is CalAmp's revenue and profitability?
- CalAmp generated $3.9M in trailing twelve-month revenue with a net loss of $86.3M, representing a net margin of -2193.7%, with free cash flow of -$47.1M. These figures are based on the Q1 2026 filing.
- Who are CalAmp's competitors?
- CalAmp's key competitors include Stoke Therapeutics, Ionis Pharmaceuticals, Rapport Therapeutics, Inc. Common Stock, and others. These companies compete in similar markets and product categories.
- Who does CalAmp partner with?
- CalAmp's notable partners include GlaxoSmithKline, Ionis Pharmaceuticals, Alnylam Pharmaceuticals, and others.
- Where is CalAmp headquartered?
- CalAmp is headquartered in United States of America. It has been publicly traded since 2024.
